These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9329539)

  • 1. New treatments and azathioprine in multiple sclerosis.
    Kolar OJ
    Lancet; 1997 Oct; 350(9083):1033. PubMed ID: 9329539
    [No Abstract]   [Full Text] [Related]  

  • 2. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect meta-analytical comparison of azathioprine and of beta interferon effectiveness in all forms of multiple sclerosis pooled together.
    Messori A; Fadda V; Maratea D; Trippoli S
    J Neurol Sci; 2014 Dec; 347(1-2):408-10. PubMed ID: 25455308
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
    Kalincik T; Horakova D; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E
    Clin Neurol Neurosurg; 2012 Sep; 114(7):940-6. PubMed ID: 22402204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multiple sclerosis--recent advances in pathogenesis and treatment].
    Itoyama Y; Fujihara K; Nakashima I; Misu T; Fujimori T; Sato S
    No To Shinkei; 2002 Jan; 54(1):5-21. PubMed ID: 11868352
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple sclerosis.
    Boggild M; Ford H
    Clin Evid; 2003 Jun; (9):1459-73. PubMed ID: 15366193
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
    Bojar M; Zajac M; Meluzínová E; Houžvičková E; Libertinová J; Lišková P; Mat'oška V; Nyč O; Mináriková M
    Mult Scler; 2010 Dec; 16(12):1529-30; author reply 1531-2. PubMed ID: 20829243
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pragmatic approach to treatments in multiple sclerosis].
    Vermersch P
    Rev Neurol (Paris); 2009 Apr; 165 Spec No 2():F125-31. PubMed ID: 19593885
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple sclerosis.
    Ford H; Nicholas R
    Clin Evid; 2005 Dec; (14):1637-51. PubMed ID: 16620466
    [No Abstract]   [Full Text] [Related]  

  • 10. New treatments for multiple sclerosis.
    Hutchinson M
    Ir Med J; 1996; 89(2):44. PubMed ID: 8682623
    [No Abstract]   [Full Text] [Related]  

  • 11. [New treatments for multiple sclerosis].
    Masdeu JC
    Rev Neurol; 1996 Jun; 24(130):708-11. PubMed ID: 8653621
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.
    Goodkin DE
    West J Med; 1994 Sep; 161(3):292-8. PubMed ID: 7975569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatments and azathioprine in multiple sclerosis.
    Palace J; Rothwell P
    Lancet; 1997 Jul; 350(9073):261. PubMed ID: 9242805
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis].
    Cendrowski W
    Neurol Neurochir Pol; 2001; 35(4 Suppl):125-38. PubMed ID: 11873611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-specific immunosuppressants in the treatment of multiple sclerosis.
    Confavreux C; Vukusic S
    Clin Neurol Neurosurg; 2004 Jun; 106(3):263-9. PubMed ID: 15177781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
    Ravnborg M; Bendtzen K; Christensen O; Jensen PE; Hesse D; Tovey MG; Sørensen PS
    Mult Scler; 2009 Mar; 15(3):323-8. PubMed ID: 19028832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How should we proceed with disease-modifying treatments for multiple sclerosis?
    Andersson PB; Waubant E; Goodkin DE
    Lancet; 1997 Mar; 349(9052):586-7. PubMed ID: 9057726
    [No Abstract]   [Full Text] [Related]  

  • 18. [Blood levels of soluble ICAM-1 in patients with multiple sclerosis].
    García-Tortosa C; Amrani Y; Casado A; Muñoz FJ; Vázquez J
    Rev Neurol; 1998 Jun; 26(154):926-9. PubMed ID: 9658462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for multiple sclerosis.
    Hughes RA
    J Neurol Neurosurg Psychiatry; 1994 Jan; 57(1):3-6. PubMed ID: 8301302
    [No Abstract]   [Full Text] [Related]  

  • 20. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
    Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
    Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.